End-of-day quote
Shenzhen S.E.
06:00:00 2024-05-28 pm EDT
|
5-day change
|
1st Jan Change
|
18.12
CNY
|
-1.74%
|
|
-6.45%
|
-17.56%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
9,836
|
17,356
|
16,742
|
10,531
|
8,675
|
7,276
|
-
|
-
|
Enterprise Value (EV)
1 |
9,836
|
16,995
|
16,342
|
10,089
|
8,176
|
6,554
|
6,186
|
5,978
|
P/E ratio
|
71.1
x
|
96.6
x
|
69.9
x
|
39.5
x
|
34.3
x
|
23.3
x
|
19
x
|
15.4
x
|
Yield
|
-
|
0.32%
|
0.3%
|
0.53%
|
0.68%
|
0.79%
|
0.96%
|
1.13%
|
Capitalization / Revenue
|
17
x
|
23.8
x
|
18.3
x
|
12.5
x
|
8.31
x
|
5.69
x
|
4.67
x
|
3.88
x
|
EV / Revenue
|
17
x
|
23.3
x
|
17.8
x
|
12
x
|
7.83
x
|
5.13
x
|
3.97
x
|
3.19
x
|
EV / EBITDA
|
52.3
x
|
73.7
x
|
56.3
x
|
30
x
|
22.7
x
|
17.4
x
|
13.8
x
|
10.9
x
|
EV / FCF
|
-
|
104
x
|
169
x
|
-
|
30.7
x
|
25.3
x
|
20.9
x
|
17
x
|
FCF Yield
|
-
|
0.96%
|
0.59%
|
-
|
3.26%
|
3.95%
|
4.8%
|
5.88%
|
Price to Book
|
10.9
x
|
15.4
x
|
12.3
x
|
7.02
x
|
5.15
x
|
3.74
x
|
3.21
x
|
2.73
x
|
Nbr of stocks (in thousands)
|
397,456
|
399,254
|
399,101
|
398,157
|
394,659
|
394,597
|
-
|
-
|
Reference price
2 |
24.75
|
43.47
|
41.95
|
26.45
|
21.98
|
18.44
|
18.44
|
18.44
|
Announcement Date
|
2/26/20
|
2/18/21
|
2/28/22
|
4/14/23
|
2/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
578.4
|
728.4
|
917
|
842.2
|
1,044
|
1,278
|
1,557
|
1,875
|
EBITDA
1 |
187.9
|
230.5
|
290.4
|
336.4
|
360.4
|
377.7
|
449.1
|
547.5
|
EBIT
1 |
162.5
|
202.1
|
253.2
|
287.7
|
295.1
|
355.7
|
423.7
|
519.8
|
Operating Margin
|
28.09%
|
27.75%
|
27.61%
|
34.16%
|
28.28%
|
27.83%
|
27.21%
|
27.72%
|
Earnings before Tax (EBT)
1 |
161.3
|
200.7
|
252
|
286.1
|
288.7
|
351.8
|
433.2
|
533.6
|
Net income
1 |
135.5
|
180.3
|
239.6
|
263.7
|
256.3
|
314.5
|
386.9
|
476.1
|
Net margin
|
23.42%
|
24.76%
|
26.12%
|
31.32%
|
24.56%
|
24.6%
|
24.84%
|
25.39%
|
EPS
2 |
0.3482
|
0.4500
|
0.6000
|
0.6700
|
0.6400
|
0.7900
|
0.9723
|
1.195
|
Free Cash Flow
1 |
-
|
162.9
|
96.91
|
-
|
266.4
|
259
|
296.6
|
351.8
|
FCF margin
|
-
|
22.37%
|
10.57%
|
-
|
25.52%
|
20.26%
|
19.05%
|
18.76%
|
FCF Conversion (EBITDA)
|
-
|
70.69%
|
33.37%
|
-
|
73.9%
|
68.57%
|
66.05%
|
64.25%
|
FCF Conversion (Net income)
|
-
|
90.34%
|
40.45%
|
-
|
103.94%
|
82.36%
|
76.68%
|
73.87%
|
Dividend per Share
2 |
-
|
0.1389
|
0.1278
|
0.1400
|
0.1500
|
0.1448
|
0.1771
|
0.2085
|
Announcement Date
|
2/26/20
|
2/18/21
|
2/28/22
|
4/14/23
|
2/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
271.3
|
206
|
186.5
|
206.8
|
242.9
|
195.2
|
263.5
|
248.9
|
336
|
233.3
|
326
|
324.8
|
397.6
|
287.4
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
56.23
|
59.06
|
46.86
|
150.3
|
31.43
|
65.49
|
79.47
|
51.65
|
98.53
|
74.95
|
90.07
|
70.61
|
90.2
|
-
|
-
|
Operating Margin
|
20.72%
|
28.66%
|
25.13%
|
72.71%
|
12.94%
|
33.56%
|
30.15%
|
20.75%
|
29.33%
|
32.13%
|
27.63%
|
21.74%
|
22.69%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
55.79
|
-
|
-
|
-
|
-
|
-
|
-
|
49.96
|
95.19
|
73.57
|
84.74
|
84.74
|
103.6
|
-
|
-
|
Net income
1 |
63.02
|
-
|
-
|
-
|
-
|
-
|
-
|
46.97
|
82.52
|
64.2
|
80.38
|
80.38
|
98.25
|
-
|
-
|
Net margin
|
23.23%
|
-
|
-
|
-
|
-
|
-
|
-
|
18.87%
|
24.56%
|
27.52%
|
24.66%
|
24.75%
|
24.71%
|
-
|
-
|
EPS
2 |
0.1611
|
0.1333
|
0.0900
|
0.3400
|
0.1100
|
0.1400
|
0.1800
|
0.1200
|
0.2000
|
0.1600
|
0.2108
|
0.1758
|
0.2432
|
0.1600
|
-
|
Dividend per Share
2 |
0.1278
|
-
|
-
|
-
|
0.1400
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.1587
|
-
|
-
|
Announcement Date
|
2/28/22
|
4/20/22
|
7/29/22
|
10/24/22
|
4/14/23
|
4/21/23
|
7/31/23
|
10/23/23
|
2/5/24
|
4/22/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
362
|
400
|
443
|
498
|
722
|
1,090
|
1,298
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
163
|
96.9
|
-
|
266
|
259
|
297
|
352
|
ROE (net income / shareholders' equity)
|
16.3%
|
17.8%
|
19.2%
|
18.4%
|
15.7%
|
16.2%
|
17.3%
|
18%
|
ROA (Net income/ Total Assets)
|
-
|
15.4%
|
16.5%
|
-
|
-
|
14.2%
|
15%
|
15.7%
|
Assets
1 |
-
|
1,170
|
1,455
|
-
|
-
|
2,214
|
2,579
|
3,028
|
Book Value Per Share
2 |
2.270
|
2.830
|
3.420
|
3.770
|
4.270
|
4.930
|
5.740
|
6.760
|
Cash Flow per Share
2 |
0.3800
|
0.5500
|
0.4200
|
0.3700
|
0.7500
|
0.6100
|
0.7500
|
1.010
|
Capex
1 |
-
|
57.8
|
71.2
|
26.4
|
32.4
|
57.8
|
52.8
|
57.9
|
Capex / Sales
|
-
|
7.93%
|
7.77%
|
3.13%
|
3.1%
|
4.52%
|
3.39%
|
3.09%
|
Announcement Date
|
2/26/20
|
2/18/21
|
2/28/22
|
4/14/23
|
2/5/24
|
-
|
-
|
-
|
Last Close Price
18.44
CNY Average target price
28.6
CNY Spread / Average Target +55.08% Consensus |
1st Jan change
|
Capi.
|
---|
| -16.11% | 1B | | -7.06% | 12.1B | | -4.07% | 8.14B | | +7.89% | 5.72B | | +27.90% | 5.51B | | -10.93% | 4.07B | | -60.67% | 2.72B | | +8.04% | 2.59B | | -10.02% | 2.34B | | +18.03% | 2.11B |
Diagnostic & Testing Substances
|